Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Colgate-Palmolive
CLConsumer StaplesGenerated Jul 5, 2026, 08:09 PM UTC
CL (Colgate-Palmolive) analytical snapshot. Return on equity 1084.91%, ROA 14.33%, ROIC 49.48%. Net income up ▲ +28.9% YoY. Debt/equity 54.06, current ratio 1.02, net debt $6.50B. Market cap $76.12B at $95.13 per share. Trailing P/E 34.34, P/S 4.75, P/B 524.98. EV/Operating income ≈ 20.74 (EV $82.63B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 1 (data confidence 81%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFundamentals
Return on equity 1084.91%, ROA 14.33%, ROIC 49.48%. Net income up ▲ +28.9% YoY. Debt/equity 54.06, current ratio 1.02, net debt $6.50B.
- Return on equity 1084.91%, ROA 14.33%, ROIC 49.48%.
- Net income up ▲ +28.9% YoY.
- Debt/equity 54.06, current ratio 1.02, net debt $6.50B.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $17.28B | — | 58.51 | 20.59 | 12.62 | $2.54B | -729.10 |
| 2017 | $16.03B | -7.2% | 58.62 | 17.39 | 8.63 | $2.26B | -569.55 |
| 2018 | — | — | — | — | — | $2.55B | -4068.33 |
| 2019 | — | — | — | — | — | $2.50B | -1984.31 |
| 2020 | — | — | — | — | — | $2.62B | 2051.28 |
| 2021 | — | — | — | — | — | $2.80B | 318.57 |
| 2022 | — | — | — | — | — | $3.31B | 442.53 |
| 2023 | — | — | — | — | — | — | 540.15 |
| 2024 | — | — | — | — | — | — | 293.10 |
| 2025 | — | — | — | — | — | — | 1084.91 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2017 | $3.76B | 0.0% | — | 15.15% |
| Jun 30, 2017 | $7.59B | -0.2% | +101.7% | 14.42% |
| Jun 30, 2017 | $3.83B | -49.7% | -49.6% | 28.59% |
| Sep 30, 2017 | $11.56B | +0.8% | +202.2% | 14.71% |
| Sep 30, 2017 | $3.97B | -65.4% | -65.6% | 42.80% |
| Mar 31, 2018 | $4.00B | +6.4% | +0.7% | 15.84% |
Filings & Ownership
Latest annual report (10-K) filed Feb 23, 2026. Latest quarterly report (10-Q) filed May 1, 2026. 12 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 23, 2026.
- Latest quarterly report (10-Q) filed May 1, 2026.
- 12 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Colgate-Palmolive; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Aug 9, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Nov 2, 2001 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 7, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 1, 2002 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 12, 2004 |
| Date | Form | Description |
|---|---|---|
| May 13, 2026 | 8-K | 8-K |
| May 1, 2026 | 8-K | 8-K |
| Apr 9, 2026 | 8-K | 8-K |
| Mar 17, 2026 | 8-K | 8-K |
| Mar 12, 2026 | 8-K | 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Nov 10, 2025 | 8-K | FORM 8-K |
| Oct 31, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 2 positive signal(s) detected from XBRL filing diff analysis. 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 20 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.63x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Gross margin expansion: Gross margin expanded +11.3%pp (from 59.3% to 70.6%), indicating improved pricing power, cost efficiency, or favorable product mix.
- Endogenous analysis: 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Going concern doubt.
- Ongoing high-severity risk language: Material weakness in internal controls.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $17.28B | $16.03B | $-1.24B | -7.2% |
| Gross profit | $10.25B | $11.33B | $1.08B | +10.5% |
| Operating income | $2.89B | $3.98B | $1.09B | +37.7% |
| Net income | $1.78B | $2.30B | $515.0M | +28.9% |
| Operating cash flow | $2.56B | $3.75B | $1.19B | +46.5% |
| Capex | $335.0M | $409.0M | $74.0M | +22.1% |
| Total assets | $16.39B | $16.05B | $-347.0M | -2.1% |
| Total liabilities | $15.44B | $15.50B | $66.0M | +0.4% |
| Long-term debt | $7.00B | $7.84B | $834.0M | +11.9% |
| Cash & equivalents | $966.0M | $1.10B | $130.0M | +13.5% |
| Stockholders equity | $609.0M | $212.0M | $-397.0M | -65.2% |
| Inventory | $1.93B | $1.99B | $53.0M | +2.7% |
| Accounts receivable | $1.59B | $1.52B | $-65.0M | -4.1% |
| R&D expense | $320.0M | $343.0M | $23.0M | +7.2% |
| SG&A expense | $6.57B | $7.15B | $586.0M | +8.9% |
| Interest expense | $184.0M | $120.0M | $-64.0M | -34.8% |
| Type | Concepts |
|---|---|
| Added | SupplierFinanceProgramObligation |
| Removed | AccrualForTaxesOtherThanIncomeTaxesCurrent, AdvertisingExpense, AllocatedShareBasedCompensationExpense, AmortizationOfIntangibleAssets, BuildingsAndImprovementsGross, CommitmentsAndContingencies, CommonStockSharesOutstanding, DeferredIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities, DeferredOtherTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 1 | 0 | NEW |
| Material weakness in internal controls | high | 20 | 2 | Ongoing |
| Impairment charge | medium | 47 | 7 | Ongoing |
| Restructuring | medium | 105 | 9 | Ongoing |
| Off-balance sheet arrangements | medium | 26 | 2 | Ongoing |
| Related party transactions | low | 7 | 1 | Ongoing |
Unlock the rest
- ProValuationMarket cap $76.12B at $95.13 per share.
- ProPrice & TechnicalsPrice $95.13 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 1
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Colgate-Palmolive is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewPrice $95.13 — uptrend (above 200-DMA); 1-month momentum positive..
Peer comparison
Defensive groupHow CL stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| CVS Health Corp. CVS | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL● you | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |
| Thermo Fisher Scientific TMO | — | Neutral |
| Danaher Corp. DHR | — | Neutral |
| Intuitive Surgical Inc. ISRG | — | Neutral |
| Vertex Pharmaceuticals VRTX | — | Neutral |
| Gilead Sciences GILD | — | Neutral |
| Zoetis Inc. ZTS | — | Neutral |
| Kimberly-Clark Corp. KMB | — | Neutral |
| Hershey Co. HSY | — | Neutral |
| Sysco Corp. SYY | — | Neutral |
| Kroger Co. KR | — | Neutral |
| Moderna Inc. MRNA | — | Neutral |
| Biogen Inc. BIIB | — | Neutral |
| DexCom Inc. DXCM | — | Neutral |
| Illumina Inc. ILMN | — | Neutral |
| HCA Healthcare HCA | — | Neutral |